Simulations Plus (SLP) witnessed a pre-market plunge of 9.84% on Wednesday, potentially driven by concerns surrounding the company's latest earnings report and an analyst downgrade.
The biopharmaceutical company reported its Q1 2025 earnings on Tuesday evening, showcasing robust growth. However, it appears that some investors were not fully satisfied with the results, leading to a selloff in the pre-market session.
Additionally, KeyBanc lowered its price target on Simulations Plus to $35 from $40, while maintaining an Overweight rating. This analyst action could have further fueled the negative sentiment surrounding the stock.
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。